Abbott Vascular (Santa Clara, California) earlier this month submitted an application for Shonin marketing authorization license to Japan's Ministry of Health, Labor and Welfare/Pharmaceuticals and Medical Devices Agency to gain approval for its Xience V everolimus-eluting coronary stent system to treat coronary artery disease.

International report: Approval in Japan sought for Xience V

Name: Relias Media
Price range: $

January 2, 2015

Reprints

Recognizing, Managing, and Reporting Pediatric Sexual Abuse and Assault
Eleventh Circuit Affirms Jury Verdict of $2.5 Million for Mesh Device Plaintiff Despite Close Call on Statute of Limitations
Indiana Appellate Court Allows Case to Proceed Against Doctor Accused of Improperly Accessing Patients’ Medical Records
Malpractice Insurance Rates Increasing After Stable Period
Clinical Decision Software Highly Effective in OR